PEOPLE ON THE MOVE
MedImmune
MedImmune, the biologics arms of AstraZeneca, has appointed David Berman head of the Oncology Innovative Medicines unit (iMED) and Senior Vice President. He will work closely with AstraZeneca’s oncology staff, succeeding Edward Bradley who will retire next year.
Berman was most recently Vice President and Head of the Immuno-Oncology Exploratory Development Team for Bristol-Myers Squibb He has also worked as a pathologist at the National Cancer Institute within the National Institute of Health.